Y1 receptor ligand-based nanomicelle as a novel nanoprobe for glioma-targeted imaging and therapy.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nanoscale

• Publication date

  2018-03-29

• Fields of study

  Medicine, Chemistry, Engineering

• Identifiers
  DOI 10.1039/c8nr00148kPMID 29542782
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• pH-Responsive Aerobic Nanoparticles for Effective Photodynamic Therapy

  2017cited by this paper
• Current Multistage Drug Delivery Systems Based on the Tumor Microenvironment

  2017cited by this paper
• Neuropeptide Y Y1 receptor-mediated biodegradable photoluminescent nanobubbles as ultrasound contrast agents for targeted breast cancer imaging.

  2017cited by this paper
• Cancer nanomedicine: progress, challenges and opportunities

  2016cited by this paper
• Self-Targeting Fluorescent Carbon Dots for Diagnosis of Brain Cancer Cells.

  2015cited by this paper
• Co-Encapsulation of Combretastatin-A4 Phosphate and Doxorubicin in Polymersomes for Synergistic Therapy of Nasopharyngeal Epidermal Carcinoma.

  2015cited by this paper
• Toward understanding and exploiting tumor heterogeneity

  2015cited by this paper
• Neuropeptide Y receptors: a promising target for cancer imaging and therapy

  2015cited by this paper
• Neuropeptide Y Y1 receptors mediate [corrected] targeted delivery of anticancer drug with encapsulated nanoparticles to breast cancer cells with high selectivity and its potential for breast cancer therapy.

  2015cited by this paper
• A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery.

  2015cited by this paper
• Synthesis and in vitro and in vivo evaluation of an (18)F-labeled neuropeptide Y analogue for imaging of breast cancer by PET.

  2015cited by this paper
• Multifunctional nanoparticles for brain tumor imaging and therapy.

  2014cited by this paper
• Neuropeptide Y receptors: how to get subtype selectivity

  2013cited by this paper
• LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma.

  2013cited by this paper
• Tumour heterogeneity in the clinic

  2013cited by this paper
• Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles.

  2012cited by this paper
• Drug Transport across the Blood–Brain Barrier

  2012cited by this paper
• Neuropeptide Y and its Y2 Receptor – Potential Targets in Neuroblastoma Therapy

  2010cited by this paper
• Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma

  2010cited by this paper
• [Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging.

  2010cited by this paper
• Breast-cancer diagnosis by neuropeptide Y analogues: from synthesis to clinical application.

  2010cited by this paper
• First selective agonist of the neuropeptide Y1‐receptor with reduced size

  2009cited by this paper
• Agonist induced receptor internalization of neuropeptide Y receptor subtypes depends on third intracellular loop and C-terminus.

  2008cited by this paper
• Neuropeptide Y Receptors in Primary Human Brain Tumors: Overexpression in High-Grade Tumors

  2008cited by this paper
• Blood-brain barrier and feeding: regulatory roles of saturable transport systems for ingestive peptides.

  2008cited by this paper
• Blood–brain barrier and chemotherapeutic treatment of brain tumors

  2006cited by this paper
• Characterization of Blood-Brain Barrier Permeability to PYY3-36 in the Mouse

  2003cited by this paper
• Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging.

  2002cited by this paper
• Novel analogues of neuropeptide Y with a preference for the Y1-receptor.

  2001cited by this paper
• Monitoring of the internalization of neuropeptide Y on neuroblastoma cell line SK-N-MC.

  2000cited by this paper
• Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme

  2000cited by this paper

• Chiral helical peptide nanomaterials: Construction strategies and applications

  2025cites this paper
• Advanced nanomicelles for targeted glioblastoma multiforme therapy.

  2025cites this paper
• Combined Strategies for Nanodrugs Noninvasively Overcoming the Blood–Brain Barrier and Actively Targeting Glioma Lesions

  2025cites this paper
• Glioma and Peptidergic Systems: Oncogenic and Anticancer Peptides

  2024cites this paper
• Current Non-Metal Nanoparticle-Based Therapeutic Approaches for Glioblastoma Treatment

  2024cites this paper
• Molecular Determinants for Photodynamic Therapy Resistance and Improved Photosensitizer Delivery in Glioma

  2024cites this paper
• Application of polymer materials in targeting glioma.

  2023cites this paper
• Transformable Neuropeptide Prodrug with Tumor Microenvironment Responsiveness for Tumor Growth and Metastasis Inhibition of Triple‐Negative Breast Cancer

  2023cites this paper
• Recent progress on near-infrared fluorescence heptamethine cyanine dye-based molecules and nanoparticles for tumor imaging and treatment.

  2023cites this paper
• Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies

  2023cites this paper
• Nanoparticle delivery systems for substance use disorder

  2022cites this paper
• A D-peptide ligand of neuropeptide Y receptor Y1 serves as nanocarrier traversing of the blood brain barrier and targets glioma

  2022cites this paper
• Chemotherapeutic nanomaterials in tumor boundary delineation: Prospects for effective tumor treatment

  2022cites this paper
• Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors

  2021cites this paper
• Strategies for Improving Stability and Pharmacokinetic Characteristics of Radiolabeled Peptides for Imaging and Therapy.

  2020cites this paper
• Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates

  2020cites this paper
• Dual and multi-targeted nanoparticles for site-specific brain drug delivery.

  2019cites this paper
• Dual ATP and pH responsive ZIF-90 nanosystem with favorable biocompatibility and facile post-modification improves therapeutic outcomes of triple negative breast cancer in vivo.

  2019cites this paper
• A Y1 receptor ligand synergized with a P-glycoprotein inhibitor improves the therapeutic efficacy of multidrug resistant breast cancer.

  2019cites this paper
• Renal-Clearable Peptide-Functionalized Ba2GdF7 Nanoparticles for Positive Tumor-Targeting Dual-Mode Bioimaging.

  2018cites this paper